Tuberculosis Diagnostics Market by Test Type (Smear Microscopy, Culture Based Tests, Nucleic Acid Testing, Mantoux Test, Radiography, Drug Susceptibility Testing, Serological Tests, IGRA), End Users (Hospitals, Laboratories, Others) and Forecast 2017-2021

Tuberculosis Diagnostics Market by Test Type (Smear Microscopy, Culture Based Tests, Nucleic Acid Testing, Mantoux Test, Radiography, Drug Susceptibility Testing, Serological Tests, IGRA), End Users (Hospitals, Laboratories, Others) and Forecast 2017-2021

Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs but TB bacteria can attack any part of the body such as the kidney, spine and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB- related conditions exist: latent TB infection(LTBI) and TB disease. TB is one of the leading causes of death worldwide. A complete medical evaluation for tuberculosis (TB) must include a medical history, a physical examination, a chest X-ray and microbiological examination (of sputum or some other appropriate sample). It may also include a tuberculin skin test, other scans and X-rays, surgical biopsy. In the year 2015–2016, the World Health Organization (WHO) recommended GeneXpert MTB/RIF, a new TB diagnostic tests as well as approved Alere’s lipoarabinomannan (LAM) test, a very affordable, simple, rapid, noninvasive, point-of-care (POC) rule-in test for people with HIV with very low CD4 counts. New versions of line-probe assays (LPAs) – Hain’s MTBDRplus and MTBDRsl and a product from Nipro (NTM+MDR-TB Detection Kit 2) have received WHO recommendations. Improvements on nucleic acid amplification tests such as GeneXpert Omni and Ultra and Molbio’s TrueNAT are being validated. Further upstream, encouraging research into gene sets that can predict active TB disease and reliably distinguish it from latent TB and other infections may eventually underpin new blood tests. Incremental advances are being made to improve the detection of pediatric TB.

The global tuberculosis diagnostics market segmentation is based on test type (smear microscopy, culture based tests, nucleic acid testing, Mantoux test, radiography, drug susceptibility testing, serological tests, IGRA, etc.), end users (hospitals, laboratories, others). The global tuberculosis diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global tuberculosis diagnostics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global tuberculosis diagnostics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global tuberculosis diagnostics market and included in this report are Abbott Laboratories, Akonni Biosystems, Inc., Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, Cepheid, Epistem plc, F. Hoffmann-La Roche Ltd., Hain Lifescience GmbH, Hologic, QIAGEN, Sanofi and Thermo Fisher Scientific, Inc.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Diagnostic Test Type
    • Indication or Infection Type
    • Technology
    • Diagnostics Application
    • Service Type
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • Device Classification I, II, III, IV
    • Device (FDA, EMEA) Approvals
  8. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  9. Recommendations
  10. References

Tuberculosis Diagnostics Market

1. Test Type
1.1 Smear Microscopy
1.2 Culture Based Tests
1.3 Nucleic Acid Testing
1.4 Mantoux Test (TuberculinSkin Test)
1.5 Radiography (Chest X-Ray)
1.6 Drug Susceptibility Testing (DST)
1.7 Other Tests (Serological Tests, IGRA)

2. End Users
2.1 Hospitals
2.2 Laboratories
2.3 Others

3. Geography (Region, Country)
3.1 North America (U.S., Canada)
3.2 Latin America (Brazil, Mexico, Rest of LA)
3.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4 Asia Pacific (Japan, China, India, Rest of APAC)
3.5 Rest of the World

4. Company Profiles
4.1 Abbott Laboratories
4.2 Akonni Biosystems, Inc.
4.3 Alere, Inc.
4.4 Beckton, Dickinson and Company
4.5 bioMerieux SA
4.6 Cepheid
4.7 Epistem Holdings Plc
4.8 Hain Lifescience GmbH
4.9 Hoffmann-La Roche Ltd.
4.10 Hologic, Inc.
4.11 Sanofi
4.12 Thermo Fisher Scientific, Inc.
4.13 Qiagen

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

Translate »